Q&A: Why the US should invest in global health innovation

A chemist tests drug samples. Photo by: Michael J. Ermarth / The U.S. Food and Drug Administration

Chagas disease — a debilitating disease caused by a parasite in the feces of the Triatominae, also known as kissing, vampire or assassin bugs — is a neglected tropical disease, a term for diseases that affect the poorest communities in the world. But this disease, endemic in rural areas of Latin America, also currently infects 300,000 people in the United States. In addition to the impact on people who become infected — including an acute phase, which usually occurs unnoticed, and a chronic stage, which develops over many years and can include intestinal and cardiac complications — the disease costs the U.S. economy an estimated $900 million annually.

There were many surprised looks in the audience when panelists mentioned the prevalence of Chagas disease in the U.S. at a global health event on Thursday in Washington, D.C. The discussion was organized by the Global Health Technologies Coalition, 25 nonprofit organizations advocating for research and development for new drugs, vaccines, diagnostics and other global health technologies to coincide with the release of a report called “Return on innovation: Why global health R&D is a smart investment for the United States.”